Abcellera Biologics Inc. Stock Price, News & Analysis

AbCellera (Nasdaq: ABCL) announced its participation in the Truist Securities AI Symposium on March 1, 2022, at 8:20 a.m. Pacific Time. The panel, titled “Integrated Platforms for AI-based Drug Discovery,” will feature executives from the Company discussing groundbreaking advancements in drug development. Interested parties can access a live audio webcast through AbCellera's Investor Relations website, with a replay available afterwards. AbCellera specializes in antibody discovery, partnering with various drug developers to expedite the development process for new treatments.

AbCellera (Nasdaq: ABCL) will present virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 12:40 p.m. PT. Investors and interested parties can access the live audio webcast on AbCellera's Investor Relations website, with a replay available afterward. AbCellera is a tech company specializing in analyzing immune systems to discover antibodies for drug development, partnering with pharmaceutical and biotechnology firms to streamline processes and address challenges in drug development.

AbCellera (Nasdaq: ABCL) has received Emergency Use Authorization (EUA) from the U.S. FDA for bebtelovimab (LY-CoV1404), its antibody treatment for mild-to-moderate COVID-19 in high-risk patients. Bebtelovimab effectively neutralizes the Omicron variant, including BA.2, demonstrating broad efficacy against circulating SARS-CoV-2 variants. The authorized dosage is 175 mg as an intravenous injection. Additionally, Lilly has contracted to supply up to 600,000 doses to the U.S. government by March 31, 2022, and an option for 500,000 more by July 31, 2022.

AbCellera (Nasdaq: ABCL) has announced a purchase agreement with Eli Lilly for the supply of up to 600,000 doses of the investigational drug bebtelovimab. The deal is valued at a minimum of $720 million and is contingent upon obtaining Emergency Use Authorization from the FDA. Testing confirms that bebtelovimab neutralizes the Omicron variant and its subvariants. This drug is part of AbCellera's rapid response to COVID-19, initiated in 2020, which also led to the development of bamlanivimab.

AbCellera (Nasdaq: ABCL) will report its full year 2021 financial results on February 24, 2022, after market close. The earnings conference call will commence at 2:00 p.m. PT (5:00 p.m. ET), with a live webcast available on AbCellera’s Investor Relations website. The company specializes in antibody development, partnering with various drug developers to enhance drug development efficiency.

AbCellera (Nasdaq: ABCL) announced changes in its Board of Directors, appointing Andrew W. Lo, Ph.D., as an independent director, while John Hamer, Ph.D., resigned. Dr. Lo, known for his innovative financial engineering and machine learning in drug development, will join the Audit and Compensation Committees. CEO Carl Hansen praised Dr. Lo's expertise in connecting financial structures with biomedical innovation. Hamer, who served since 2018, was acknowledged for his valuable contributions. These changes aim to enhance AbCellera's strategic direction in antibody therapy development.

AbCellera (Nasdaq: ABCL) announced an expanded Emergency Use Authorization (EUA) from the FDA for the combination of bamlanivimab and etesevimab for pediatric patients under 12, including neonates. The EUA permits treatment for mild to moderate COVID-19 and post-exposure prophylaxis. Data from the BLAZE-1 Phase 2/3 clinical trial indicated a median symptom resolution of 7 days. The treatment shows efficacy against the Delta variant, currently prevalent in the U.S.

AbCellera (Nasdaq: ABCL) has appointed Neil Aubuchon as the new Chief Commercial Officer, bringing over 20 years of experience from renowned biopharmaceutical firms like Amgen and Eli Lilly. His role will focus on enhancing the company's commercial strategy and optimizing partnership opportunities for antibody-based therapies.

CEO Carl Hansen expressed confidence in Aubuchon's ability to evaluate and grow their portfolio. This strategic leadership change promises to strengthen AbCellera's market position in the evolving landscape of drug development.

AbCellera (Nasdaq: ABCL) reported Q3 2021 revenue of $5.5 million, down from $9.4 million in Q3 2020, attributed to reduced milestone payments from COVID-19 treatments. The company experienced a net loss of $21.4 million or ($0.08) per share, worsening from a net loss of $2.7 million or ($0.02) per share last year. Despite these losses, AbCellera achieved significant growth in its program starts and partnerships, adding 17 new programs and bringing cumulative program starts to 69. The firm retains a strong liquidity position with $753.5 million in cash and marketable securities.